The effect of empagliflozin laboratory findings

Phase 3

• Conditions: Condition 1: Diabetes Mellitus type 2. Condition 2: Coronary artery disease.; Type 2 diabetes mellitus; Atherosclerotic heart disease of native coronary artery; I125.1

• Registration Number: IRCT20190412043247N1
• Lead Sponsor: Zanjan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 5 November 2019

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

Age between 40-75 year-old
HbA1c between 6.5 to 9
Diabetes mellitus type 2
Under fix continues treatment for at least 3 month
BMI less than 40
Fixed Diet and physical activity

Exclusion Criteria

Pregnancy
Heart Failure (NYHA class 3-4)
History of allergic reaction to SGLT2 inhibitors Drugs
History of SGLT2 inhibitor Drugs usage
GFR< 45
Gastrointestinal malabsorbtion disease
History of CABG, ACS, TIA,CVA or PCI during past 3 month
History of mallingnacy
Severe HTN
Hb<10
History of heart or lung transplant
Major psychiatric disorders
History of DKA
Elevated liver enzymes >3 times upper normal limit
Presence of urinary-genital infection
History of infection less than 1 month prior to the study
History of Anti-inflammatory drugs

Study & Design

• Study Type: interventional
• Study Design: Not specified